Home > Publications database > Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. > print

001     128633
005     20240228145542.0
024 7 _ |a 10.1038/onc.2017.110
|2 doi
024 7 _ |a pmid:28504719
|2 pmid
024 7 _ |a pmc:PMC5605674
|2 pmc
024 7 _ |a 0950-9232
|2 ISSN
024 7 _ |a 1476-5594
|2 ISSN
024 7 _ |a altmetric:20166857
|2 altmetric
037 _ _ |a DKFZ-2017-04649
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Kawauchi, Daisuke
|0 P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b
|b 0
|e First author
|u dkfz
245 _ _ |a Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
260 _ _ |a Basingstoke
|c 2017
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1510738639_15361
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Group3 medulloblastoma (MBG3) that predominantly occur in young children are usually associated with MYC amplification and/or overexpression, frequent metastasis and a dismal prognosis. Physiologically relevant MBG3 models are currently lacking, making inferences related to their cellular origin thus far limited. Using in utero electroporation, we here report that MBG3 mouse models can be developed in situ from different multipotent embryonic cerebellar progenitor cells via conditional expression of Myc and loss of Trp53 function in several Cre driver mouse lines. The Blbp-Cre driver that targets embryonic neural progenitors induced tumors exhibiting a large-cell/anaplastic histopathology adjacent to the fourth ventricle, recapitulating human MBG3. Enforced co-expression of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic neuronal progenitors as well as cerebellar granule cells give rise to MBG3 with their distinct growth kinetics. Cross-species gene expression analysis revealed that these novel MBG3 models shared molecular characteristics with human MBG3, irrespective of their cellular origin. We here developed MBG3 mouse models in their physiological environment and we show that oncogenic insults drive this MB subgroup in different cerebellar lineages rather than in a specific cell of origin.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a MYC protein, human
|2 NLM Chemicals
650 _ 7 |a Myc protein, mouse
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins c-myc
|2 NLM Chemicals
700 1 _ |a Ogg, R. J.
|b 1
700 1 _ |a Liu, L.
|b 2
700 1 _ |a Shih, D. J. H.
|b 3
700 1 _ |a Finkelstein, D.
|b 4
700 1 _ |a Murphy, B. L.
|b 5
700 1 _ |a Rehg, J. E.
|b 6
700 1 _ |a Korshunov, A.
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 7
|u dkfz
700 1 _ |a Calabrese, C.
|b 8
700 1 _ |a Zindy, F.
|b 9
700 1 _ |a Phoenix, T.
|b 10
700 1 _ |a Kawaguchi, Y.
|b 11
700 1 _ |a Gronych, J.
|0 P:(DE-He78)bb186a8b38fef24ebd6f11918ade985d
|b 12
|u dkfz
700 1 _ |a Gilbertson, R. J.
|b 13
700 1 _ |a Lichter, P.
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 14
|u dkfz
700 1 _ |a Gajjar, A.
|b 15
700 1 _ |a Kool, M.
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 16
|u dkfz
700 1 _ |a Northcott, P. A.
|b 17
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 18
|u dkfz
700 1 _ |a Roussel, M. F.
|b 19
773 _ _ |a 10.1038/onc.2017.110
|g Vol. 36, no. 37, p. 5231 - 5242
|0 PERI:(DE-600)2008404-3
|n 37
|p 5231 - 5242
|t Oncogene
|v 36
|y 2017
|x 1476-5594
909 C O |o oai:inrepo02.dkfz.de:128633
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)bb186a8b38fef24ebd6f11918ade985d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOGENE : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOGENE : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21